Epithelial membrane antigen (EMA) (Heyderman et al., 1979 ) is a membrane component expressed by most epithelial cells, by all breast carcinomas and their metastases but not by the vast majority of normal bone marrow cells (Sloane et al., 1980 (Goding, 1976) . Briefly a 1% solution of chromium chloride (CrCl3) in 0.9% sodium chloride (NaCl) was adjusted to pH 5 by the addition of 1 N sodium hydroxide twice-weekly for 3 weeks, then stored without further adjustment in a dark container. A 0.1% solution in 0.9% NaCl was prepared freshly from this stock just prior to use. Erythrocytes from fresh heparinised blood taken from healthy volunteers were washed 4 x in 0.9% saline, and then pelleted. An aliquot of 85 p1 of the packed RBC pellet was then resuspended in a suitable volume of 0.9% saline so that when the SaM and the CrCl3 were added the resulting volume was 2ml. The antibody used was a heteroantiserum sheep-anti-mouse-immunoglobulin (SaM) dialysed extensively against 0.9% NaCl. An aliquot (0.5mg) of this antibody was added and followed immediately by 135pl of fresh 0.1% CrCl3. After 5 min at room temperature with occasional agitation, the reaction was quenched with 3-5 ml of PBS, and red cells were washed twice in PBS and resuspended in 5ml of medium. The red cells now coupled to SaM (RBC.SaM) were stored on ice overnight for use within 24 h.
Epithelial membrane antigen (EMA) (Heyderman et al., 1979 ) is a membrane component expressed by most epithelial cells, by all breast carcinomas and their metastases but not by the vast majority of normal bone marrow cells (Sloane et al., 1980) . It has been shown that immunocytochemical staining for EMA can detect very small numbers of breast cancer in bone marrow smears that appear normal by conventional haematological techniques (Dearnaley et al., 1981) .
However, because bone marrow infiltration by breast cancer is patchy involving some sites and not others (Brunning et al., 1975) , we have found that aspirates must be taken from multiple sites to avoid sampling error. The examination of such largevolume samples is time-consuming because of the number of smears produced and we therefore sought a process to concentrate the malignant cells. This paper describes a rosetting technique utilising a monoclonal antibody (anti-HLe-l) which recognises an antigen present on almost all normal narrow cells but not on an any malignant or epithelial cells (Beverley, 1980) . Using this antibody to form rosettes 95-98% of marrow cells can be removed producing a smaller number of smears. We have compared the rosetting technique with density separation over lymphoprep previously described (Dearnaley et al., 1981 (Goding, 1976 (Beverley, 1980) . Studies using cell-lines and human tissues had shown no crossreactivity with breast cancer or other epithelial tissues (Beverley, 1980 The marrow aspirate/RBC.SaM mixture, after removal of the Percoll cushion, was gently resuspended by inverting the tube 3 times. Then 10ml of Ficoll-Hypaque of density 1.100 was underlayered. The samples were then centrifuged at 400 g for 20min. The cells retained at the interface were then prepared for staining in the same way as those in the density method.
Immunocytochemical staining for EMA has already been described (Dearnaley et al., 1981) . Briefly, the endogenous alkaline phosphatase activity of osteoblasts was blocked by periodic acid, acetic acid and levamisole and the cells incubated with rabbit anti-EMA at 1:1000 dilution. After washing they were incubated with goat-anti-rabbitimmunoglobulin conjugated to alkaline phosphatase and the colour reaction developed by using Table II compares the number of positive samples detected by the two methods. The rosette method produced a false negative result in 11 patients in whom malignant cells were detected by the density method and did not yield any positive samples when the density method was negative. Figure 1 it can be seen that the rosetting technique produced a negative result when there were only small numbers of malignant cells present (<6 cells). However, when larger numbers of cells were present both the rosetting and the density method yielded positive results. Table III compares the results of the density method with the clinical status of the patients. It can be seen that 20% of patients with primary breast cancer with no evidence of metastases had demonstrable malignant cells in their marrow by analysis of multiple aspirates using the density method. Eighty percent of patients with known bony metastases in the single aspirate series and 75% of patients with other metastases in the multiple aspirate series had positive samples. The negative rosetting technique described here clearly offers a highly selective method of removing haematological cells from a cell suspension or marrow sample. Unfortunately, it may be of limited value in the early detection of metastatic spread of breast cancer to bone marrow since when 6 or less malignant cells are present in the sample, they are likely to be lost into the pellet instead of being retained at the interface.
The rosetting rechnique was devised in order to minimise the problem of non-specific nucleated cell loss, and the high density separation medium FH 1.100 is the highest density that will allow separation or erythrocytes so that further improvement or resolution of the problem is not likely with this technique.
From the clinical point of view, the significance of any malignant cells in the marrow can only be defined after long-term follow-up of these patients. Since there are no data to suggest any clinically significant "threshold" for malignant cells in the marrow, we felt that it would not be advisable to However, there are other tumours in which it would be greatly desirable to detect early invasion of the bone marrow. This technique may be more suitable for tumours such as small cell carcinoma of the lung (SCCL) where the number of cells found in marrow is generally higher and where marrow involvement is more commonly detected by conventional staining. At the time of writing, there are no exceptionally useful monoclonal antibodies raised for the identifying metastatic cells from SCCL. However, workers at two centres are active in this field and both are planning to use the antiHLe-1 rosetting technique to look for small numbers of malignant cells in patients with SCCL and apparently limited disease. Provided the cell numbers are larger than in breast cancer, the technique may be of value.
Negative rosetting may also have a role in the selective removal of leukocytes from cell mixtures. It has been used in this way to produce pure tumour cell populations from digests of metastatic lymph nodes and has enabled us to study cell surface antigens of pure human tumour cell populations.
